Drug Trial Radar · NCT06383078
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 20, 2024
Primary completion
Mar 1, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.
Conditions
- Efficacy and Safety
Interventions
HR070803Drug
HR070803 60 mg/\^2 D1 over 90 minutes.
OxaliplatinDrug
Oxaliplatin 85 mg/\^2 D1 over 2 hours.
TegafurDrug
initial dose of S-1 is determined according to the body surface area,orally, D1-7.
Folinic acidDrug
Folinic acid 400 mg/\^2 D1
5-FluorouracilDrug
5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1-year Disease-free survival rateTime frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.